---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-169513"
form_type: "8-K"
ticker: "CTKB"
cik: "0001831915"
company_name: "Cytek Biosciences, Inc."
filed_at: "2023-06-20T23:59:59+00:00"
generated_at: "2026-06-13T21:43:26.084137+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Cytek Biosciences shareholders elect three Class II directors and approve say-on-pay

## Summary
- All three director nominees (Jack Ball, Vera Imper, Ming Yan) elected with 55.9M–56.9M votes for; broker non-votes 25.6M.
- Advisory vote on 2022 executive compensation passed with 57.4M for, 1.4M against, 0.8M abstentions.
- Advisory vote on frequency of say-on-pay: one-year option received 58.6M votes; two- and three-year options negligible.
- Ratification of Deloitte & Touche as auditor for FY2023 approved with 84.9M for, 11k against.
- Approximately 63% of outstanding shares (85.2M of 135.7M) represented at the 2023 annual meeting.

## SEC filing metadata
- accession: 0001193125-23-169513
- form_type: 8-K
- ticker: CTKB
- cik: 0001831915
- company_name: Cytek Biosciences, Inc.
- filed_at: 2023-06-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831915/000119312523169513/0001193125-23-169513-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831915/000119312523169513/d483871d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-169513
- JSON: https://secwatch.observer/filing/0001193125-23-169513.json
- Plain text: https://secwatch.observer/filing/0001193125-23-169513.txt

## Key facts
- Shareholder Votes
  Cytek Biosciences, Inc. shareholders approved Frequency of Stockholder Vote on Executive Compensation (advisory vote) at the 2023-06-14 meeting.
  - Proposal: say on pay frequency
  - Outcome: passed
  - Meeting: 2023-06-14
  source text: 3. Frequency of Stockholder Vote on Executive Compensation. On an advisory basis, a one-year frequency of future advisory votes on the compensation of the Company’s named executive officers was approved based on the following results of voting: One Year Two Years Three Years Abstentions Broker Non-Votes 58,649,562 109,046 165,909 686,914 25,604,540
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831915/000119312523169513/0001193125-23-169513-index.htm
- Shareholder Votes
  Cytek Biosciences, Inc. shareholders approved Executive Compensation (advisory vote) at the 2023-06-14 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-06-14
  source text: 2. Executive Compensation. On an advisory basis, compensation paid to the Company’s named executive officers for the year ended December 31, 2022 was approved based on the following results of voting: Votes For Votes Against Abstentions Broker Non-Votes 57,420,396 1,390,622 800,413 25,604,540
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831915/000119312523169513/0001193125-23-169513-index.htm
- Shareholder Votes
  Cytek Biosciences, Inc. shareholders approved Election of Class II Directors at the 2023-06-14 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-14
  source text: 1. Election of Class II Directors. Each of the following nominees was elected to serve as a Class II director, to hold office until the Company’s 2026 annual meeting of stockholders or until his or her successor has been duly elected and qualified or his or her earlier death, resignation or removal: Nominee Votes For Votes Withheld Broker Non-Votes Jack Ball 55,857,084 3,754,347 25,604,540 Vera Imper, Ph.D. 49,090,622 10,520,809 25,604,540 Ming Yan, Ph.D. 56,925,027 2,686,404 25,604,540
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831915/000119312523169513/0001193125-23-169513-index.htm
- Shareholder Votes
  Cytek Biosciences, Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2023-06-14 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-14
  source text: 4. Ratification of the Selection of Independent Registered Public Accounting Firm. The selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified based on the following results of voting: Votes For Votes Against Abstentions Broker Non-Votes 84,894,550 11,239 310,182 —
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831915/000119312523169513/0001193125-23-169513-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.